KEYNOTE-045, trial summary

A randomised clinical trial investigating the effect of pembrolizumab versus investigator’s choice of chemotherapy in

NCT02256436    N Engl J Med 2017 Feb 17;:  




Studied treatment
Control treatment



Patients
Group sizes -9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI0,22,01,0


Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017 Feb 17;:     [PMID: 28212060]   link to pdf  



Registering number NCT02256436 (see trial on clinicaltrials.gov)
Code Name

 




Appears in following systematic reviews: